Long-Term Efficacy of Radionuclide Therapy in Patients with Disseminated Neuroendocrine Tumors Uncontrolled by Conventional Therapy
Charles Nguyen, MD1,
Marc Faraggi, MD, PhD2,
Anne-Laure Giraudet, MD3,
Claire de Labriolle-Vaylet, MD, PhD4,
Thomas Aparicio, MD5,
François Rouzet, MD2,
Michel Mignon, MD, PhD5,
Serge Askienazy, MD, PhD1 and
Iradj Sobhani, MD, PhD6
1 Service de Médecine Nucléaire, Centre Hospitalier et Universitaire de Saint-Antoine, Paris, France
2 Service de Médecine Nucléaire, Centre Hospitalier et Universitaire de Bichat, Paris, France
3 Service de Médecine Nucléaire, Centre Hospitalier et Universitaire de Cochin, Paris, France
4 Service de Médecine Nucléaire, Hôpital Trousseau, Paris, France
5 Service d’Hépato-gastro-entérologie, Centre Hospitalier et Universitaire de Bichat, Paris, France
6 Service d’Hépato-gastro-entérologie, Centre Hospitalier et Universitaire de Henri Mondor, Créteil, France
View larger version (12K):
[in a new window]
|
FIGURE 1. Overall Kaplan–Meier survival curves of patients in group A (treated) and group B (nontreated) (P = 0.019).
|
|
View larger version (101K):
[in a new window]
|
FIGURE 2. (A) 131I-MIBG imaging of patient 18 during radionuclide therapy shows high uptake in multiple liver metastases and primary site. (B) Fifteen months later, 123I-MIBG imaging shows partial remission, with only faint uptake in primary site.
|
|
View larger version (14K):
[in a new window]
|
FIGURE 3. Progression-free Kaplan–Meier survival curves of patients in group A (treated) and group B (nontreated) (P = 0.024).
|
|
View larger version (14K):
[in a new window]
|
FIGURE 4. Event-free Kaplan–Meier survival curves of patients in group A (treated) and group B (nontreated) (P = 0.019).
|
|
Copyright © 2004 by the Society of Nuclear Medicine.
